Creatine has long been recognized as one of the most effective supplements for improving strength, muscle performance, and recovery. Now, new research from UCLA suggests that creatine may also play an important role in supporting the body's immune response against cancer.

The findings, published in iScience and highlighted by UCLA Newsroom, reveal that creatine helps energize immune cells responsible for detecting tumors and activating the body's natural cancer-fighting defenses. While the results are promising, researchers emphasize that the work is still in the preclinical stage and should not be interpreted as a cancer treatment.

Understanding the Role of Dendritic Cells

The immune system relies on specialized cells called dendritic cells to recognize threats inside the body. These cells act as messengers by identifying cancer cells and activating killer T cells, which are responsible for attacking and destroying tumors.

Inside tumors, nutrients are scarce, making it difficult for dendritic cells to function effectively. UCLA researchers found that these immune cells increase their uptake of creatine to meet their energy demands in this challenging environment.

How Creatine Supports Immune Function

Creatine helps produce ATP (adenosine triphosphate), the primary energy source used by cells.

According to the UCLA study, higher creatine availability enabled dendritic cells to:

• Produce more cellular energy (ATP)
• Survive longer inside tumors
• Activate more killer T cells
• Strengthen the overall immune response against cancer

Researchers describe creatine as acting like an energy reserve, allowing immune cells to continue functioning even when nutrients are limited.

Key Findings from the UCLA Study

The research produced several important observations:

• Creatine supplementation significantly slowed melanoma tumor growth in mouse models.
• Tumors contained higher numbers of active dendritic cells after creatine treatment.
• Human dendritic cells grown in laboratory conditions became more effective at activating T cells when exposed to creatine.
• Creatine may improve the effectiveness of dendritic cell-based cancer vaccines and complement existing immunotherapy treatments.

Why This Research Matters

Current cancer immunotherapies are highly effective for some patients but not for everyone. Researchers estimate that only about 20% to 40% of patients respond well to many existing immunotherapy treatments.

By improving the function of dendritic cells—the cells responsible for initiating the immune response—creatine could potentially enhance future immunotherapy approaches and help more patients benefit from these treatments.

Important Limitations

Despite the exciting findings, several important limitations remain:

• The study was conducted using mouse models and human cells in laboratory settings.
• No clinical evidence currently shows that creatine treats or prevents cancer in humans.
• Human clinical trials are still required before creatine can be recommended as part of cancer therapy.
• Patients undergoing cancer treatment should always consult their healthcare provider before starting any dietary supplement.

Conclusion

The UCLA study highlights a fascinating new role for creatine beyond sports nutrition. By supplying energy to dendritic cells, creatine may strengthen the immune system's ability to recognize and fight cancer, potentially improving future immunotherapy strategies.

Although these findings represent an important scientific advance, they remain early-stage research. More clinical studies in humans are needed before creatine can be considered a therapeutic option for cancer patients.